Novartis (NVS) Projected to Post Quarterly Earnings on Wednesday

Novartis (NYSE:NVS) will likely be posting its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of $1.97 per share and revenue of $13.8502 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 1:00 AM ET.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.26 by ($0.01). The company had revenue of $14.36 billion during the quarter, compared to the consensus estimate of $13.70 billion. Novartis had a return on equity of 41.21% and a net margin of 26.49%.The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.06 earnings per share. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Novartis Trading Up 2.0%

NYSE NVS opened at $152.08 on Wednesday. The company has a current ratio of 0.88, a quick ratio of 0.68 and a debt-to-equity ratio of 0.50. The stock has a market cap of $321.27 billion, a PE ratio of 20.78, a PEG ratio of 1.94 and a beta of 0.51. The company’s 50-day moving average price is $137.06 and its 200-day moving average price is $129.08. Novartis has a 12 month low of $97.71 and a 12 month high of $152.48.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of NVS. Measured Wealth Private Client Group LLC purchased a new stake in shares of Novartis in the third quarter valued at approximately $33,000. Pin Oak Investment Advisors Inc. lifted its holdings in shares of Novartis by 25.2% in the third quarter. Pin Oak Investment Advisors Inc. now owns 462 shares of the company’s stock valued at $59,000 after purchasing an additional 93 shares in the last quarter. Kelleher Financial Advisors purchased a new position in Novartis during the third quarter worth $75,000. Triumph Capital Management purchased a new stake in Novartis during the 3rd quarter worth about $79,000. Finally, Larson Financial Group LLC lifted its stake in shares of Novartis by 34.3% during the third quarter. Larson Financial Group LLC now owns 1,420 shares of the company’s stock valued at $182,000 after buying an additional 363 shares during the period. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVS has been the topic of several recent analyst reports. Barclays raised Novartis from an “underweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. JPMorgan Chase & Co. raised shares of Novartis from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. HC Wainwright lowered shares of Novartis to a “neutral” rating in a report on Monday, October 27th. Cfra Research upgraded Novartis to a “hold” rating in a research note on Wednesday, October 29th. Finally, Citigroup initiated coverage on shares of Novartis in a research report on Tuesday. They set a “buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Novartis has an average rating of “Hold” and an average price target of $119.75.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.